Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial

✍ Scribed by Amadori, Dino; Aglietta, Massimo; Alessi, Barbara; Gianni, Lorenzo; Ibrahim, Toni; Farina, Gabriella; Gaion, Fernando; Bertoldo, Francesco; Santini, Daniele; Rondena, Roberta; Bogani, Paola; Ripamonti, Carla I

• Book ID: 120468985
• Publisher: The Lancet
• Year: 2013
• Tongue: English
• Weight: 265 KB
• Volume: 14
• Category: Article
• ISSN: 1470-2045
• DOI: 10.1016/S1470-2045(13)70174-8